ECSP11010770A - Compuesto heterocíclico y su uso - Google Patents

Compuesto heterocíclico y su uso

Info

Publication number
ECSP11010770A
ECSP11010770A EC2011010770A ECSP11010770A ECSP11010770A EC SP11010770 A ECSP11010770 A EC SP11010770A EC 2011010770 A EC2011010770 A EC 2011010770A EC SP11010770 A ECSP11010770 A EC SP11010770A EC SP11010770 A ECSP11010770 A EC SP11010770A
Authority
EC
Ecuador
Prior art keywords
heterocyclic compound
hypertension
prodrugs
formulas
symbol
Prior art date
Application number
EC2011010770A
Other languages
English (en)
Inventor
Takanobu Kuroita
Yasuhiro Imaeda
Kouichi Iwanaga
Hidekazu Tokuhara
Yoshiyuki Fukase
Naohiro Taya
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41282529&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11010770(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of ECSP11010770A publication Critical patent/ECSP11010770A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Compuestos representados por las fórmulasen donde cada símbolo es como se definió en la memoria descriptiva y uno de sus profármacos tiene una actividad inhibidora de renina superior y son de utilidad como agentes para la prevención o el tratamiento de hipertensión, diversos daños orgánicos atribuibles a la hipertensión, y similares.
EC2011010770A 2008-06-19 2011-01-19 Compuesto heterocíclico y su uso ECSP11010770A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008161049 2008-06-19
JP2009004882 2009-01-13

Publications (1)

Publication Number Publication Date
ECSP11010770A true ECSP11010770A (es) 2011-02-28

Family

ID=41282529

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011010770A ECSP11010770A (es) 2008-06-19 2011-01-19 Compuesto heterocíclico y su uso

Country Status (38)

Country Link
US (5) US8664380B2 (es)
EP (1) EP2297114B1 (es)
JP (3) JP4800445B2 (es)
KR (2) KR101207830B1 (es)
CN (2) CN102123990B (es)
AR (1) AR072166A1 (es)
AU (1) AU2009261153B2 (es)
BR (1) BRPI0914802B8 (es)
CA (1) CA2728476C (es)
CL (1) CL2010001361A1 (es)
CO (1) CO6300862A2 (es)
CR (2) CR20110001A (es)
CY (1) CY1120995T1 (es)
DK (1) DK2297114T3 (es)
DO (2) DOP2010000381A (es)
EA (2) EA019755B1 (es)
EC (1) ECSP11010770A (es)
ES (1) ES2676289T3 (es)
GE (2) GEP20135957B (es)
HR (1) HRP20181370T1 (es)
HU (1) HUE039416T2 (es)
IL (1) IL209282A (es)
JO (1) JO3465B1 (es)
LT (1) LT2297114T (es)
MA (1) MA32483B1 (es)
MX (2) MX2010013602A (es)
MY (1) MY160771A (es)
NZ (2) NZ589825A (es)
PE (2) PE20110067A1 (es)
PL (1) PL2297114T3 (es)
PT (1) PT2297114T (es)
RS (1) RS57591B1 (es)
SG (1) SG188117A1 (es)
SI (1) SI2297114T1 (es)
TW (2) TWI378096B (es)
UY (1) UY31907A (es)
WO (1) WO2009154300A2 (es)
ZA (1) ZA201009073B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009051112A1 (ja) 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited アミド化合物およびその用途
TWI434690B (zh) 2007-12-19 2014-04-21 Dainippon Sumitomo Pharma Co 雜雙環衍生物
TWI378096B (en) 2008-06-19 2012-12-01 Takeda Pharmaceutical Heterocyclic compound and use thereof
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
KR20120109292A (ko) 2009-06-24 2012-10-08 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Ｎ-치환-시클릭 아미노 유도체
TW201130852A (en) * 2009-12-23 2011-09-16 Abbott Lab Novel thienopyrrole compounds
AU2011266099B2 (en) * 2010-06-16 2014-09-11 Takeda Pharmaceutical Company Limited Crystal of amide compound
US8742097B2 (en) * 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
CN103189370B (zh) * 2010-11-09 2015-07-08 霍夫曼-拉罗奇有限公司 作为gaba受体用配体的***衍生物
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
CN107879941A (zh) * 2012-02-14 2018-04-06 陶氏环球技术有限责任公司 非离子型表面活性剂组合物
CN104254322B (zh) * 2012-02-15 2017-06-13 武田药品工业株式会社 片剂
US9475797B2 (en) * 2012-06-26 2016-10-25 Saniona A/S Phenyl triazole derivative and its use for modulating the GABAA receptor complex
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
CA2944779A1 (en) * 2014-04-10 2015-10-15 Takeda Pharmaceutical Company Limited Method for producing heterocyclic compound
EP3140316A1 (en) 2014-05-05 2017-03-15 Thetis Pharmaceuticals LLC Compositions and methods relating to ionic salts of peptides
CN107074884A (zh) 2014-06-18 2017-08-18 西蒂斯制药有限责任公司 活性剂的矿物质氨基酸复合物
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
DK3454907T3 (da) 2016-06-03 2020-10-19 Thetis Pharmaceuticals Llc Sammensætninger og fremgangsmåder relateret til salte af specialiserede pro-løsningsmediatorer af inflammation
CN108727249A (zh) * 2018-07-07 2018-11-02 台州学院 3-二氟甲基哌啶盐酸盐及其衍生物的合成方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
RU2168510C2 (ru) 1991-07-31 2001-06-10 Такеда Кемикал Индастриз, Лтд. Гетероциклическое соединение, фармацевтическая композиция, способ антагонизирования ангиотензина ii
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
DE69522718T2 (de) 1995-06-06 2002-02-07 Pfizer Substituierte n-(indol-2-carbonyl)-amide und derivate als glycogen phosphorylase inhibitoren
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
IL120724A0 (en) 1995-09-01 1997-08-14 Lilly Co Eli Indolyl neuropeptide Y receptor antagonists
TWI227240B (en) 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
US20030078278A1 (en) 2001-06-26 2003-04-24 Pfizer Inc. Spiropiperidine compounds as ligands for ORL-1 receptor
WO2003037274A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides
US20030171411A1 (en) 2001-12-21 2003-09-11 Kodra Janos Tibor Amide derivatives as therapeutic agents
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
CA2500848A1 (en) 2002-10-18 2004-05-06 Merck & Co., Inc. Mitotic kinesin inhibitors
US20040204455A1 (en) 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
WO2004111033A1 (en) * 2003-06-18 2004-12-23 Astrazeneca Ab 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
ES2319429T3 (es) 2003-08-15 2009-05-07 MERCK & CO., INC. Inhibidores de cinesina mitotica.
US7666862B2 (en) 2003-08-15 2010-02-23 Merck & Co., Inc. Mitotic Kinesin Inhibitors
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
WO2005047251A1 (en) 2003-11-12 2005-05-26 Lg Life Sciences Ltd. Melanocortin receptor agonists
AR053406A1 (es) 2004-07-09 2007-05-09 Speedel Experimenta Ag Derivados de piperidina como inhibidores de renina. composiciones farmaceuticas
MX2007001540A (es) 2004-08-10 2007-04-23 Incyte Corp Compuestos amido y sus usos como farmaceuticos.
WO2006042150A1 (en) 2004-10-07 2006-04-20 Vitae Pharmaceuticals, Inc. Diaminoalkane aspartic protease inhibitors
JP2008520732A (ja) * 2004-11-23 2008-06-19 ワイス ゴナドトロピン放出ホルモン受容体アンタゴニスト
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
CA2599390A1 (en) 2005-03-16 2006-09-28 Merck & Co., Inc. Mitotic kinesin inhibitors
GB0511063D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514203D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
JP5220414B2 (ja) * 2005-08-30 2013-06-26 旭化成ファーマ株式会社 スルホンアミド化合物
FI20055498A0 (fi) 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
PT2420491E (pt) 2005-12-30 2013-10-14 Novartis Ag Compostos de piperidina 3,5-substituída como inibidores de renina
TW200804359A (en) 2006-01-19 2008-01-16 Speedel Experimenta Ag Substituted 4-phenylpiperidines
US20100121048A1 (en) 2006-02-16 2010-05-13 Takanobu Kuroita Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension
US7790884B2 (en) * 2006-03-24 2010-09-07 Astellas Pharma Inc. Acylaminopiperidine compound
GB0607954D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
WO2008009954A1 (en) 2006-07-21 2008-01-24 Astex Therapeutics Limited Medical use of cyclin dependent kinases inhibitors
WO2008016666A2 (en) * 2006-08-02 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
EP2119702A4 (en) 2007-01-31 2010-12-08 Dainippon Sumitomo Pharma Co amide derivative
JP4837701B2 (ja) 2007-04-20 2011-12-14 田辺三菱製薬株式会社 医薬組成物
US20090156612A1 (en) 2007-04-27 2009-06-18 Takanobu Kuroita Substituted imidazole compound and use thereof
JP2010163361A (ja) * 2007-04-27 2010-07-29 Dainippon Sumitomo Pharma Co Ltd キノリン誘導体
JP2010189275A (ja) 2007-06-14 2010-09-02 Dainippon Sumitomo Pharma Co Ltd ナフタレン誘導体
TWI452044B (zh) 2007-06-15 2014-09-11 Mitsubishi Tanabe Pharma Corp 嗎啉衍生物
WO2009001915A1 (ja) 2007-06-28 2008-12-31 Takeda Pharmaceutical Company Limited 置換イミダゾール化合物およびその用途
JP2010208947A (ja) * 2007-06-29 2010-09-24 Dainippon Sumitomo Pharma Co Ltd キノロン誘導体
JP2010229034A (ja) * 2007-07-26 2010-10-14 Dainippon Sumitomo Pharma Co Ltd 二環性ピロール誘導体
WO2009051112A1 (ja) 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited アミド化合物およびその用途
JP2011037712A (ja) 2007-12-08 2011-02-24 Dainippon Sumitomo Pharma Co Ltd ４−アリールフェニル誘導体
TWI434690B (zh) * 2007-12-19 2014-04-21 Dainippon Sumitomo Pharma Co 雜雙環衍生物
AR070454A1 (es) 2008-02-27 2010-04-07 Nycomed Gmbh Pirrolopirimidincarboxamidas y composiciones farmaceuticas que las comprenden
US20110098288A1 (en) 2008-03-11 2011-04-28 Jeremy Major Sulfonamides as zap-70 inhibitors
JP2009298713A (ja) * 2008-06-11 2009-12-24 Daiichi Sankyo Co Ltd イミダゾチアゾール誘導体
TWI378096B (en) * 2008-06-19 2012-12-01 Takeda Pharmaceutical Heterocyclic compound and use thereof
WO2010126002A1 (ja) 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬

Also Published As

Publication number Publication date
GEP20166443B (en) 2016-03-10
SG188117A1 (en) 2013-03-28
DOP2013000123A (es) 2013-11-15
LT2297114T (lt) 2018-08-10
EA201301040A1 (ru) 2014-01-30
US9221836B2 (en) 2015-12-29
DOP2010000381A (es) 2010-12-31
KR20120084778A (ko) 2012-07-30
JP4800445B2 (ja) 2011-10-26
MX338557B (es) 2016-04-21
CA2728476C (en) 2017-03-21
AU2009261153B2 (en) 2014-05-22
TW201002685A (en) 2010-01-16
CL2010001361A1 (es) 2011-07-29
KR20110019428A (ko) 2011-02-25
EP2297114B1 (en) 2018-06-06
HRP20181370T1 (hr) 2018-10-19
CR20130360A (es) 2013-09-03
IL209282A (en) 2015-07-30
JP2011157391A (ja) 2011-08-18
US8466282B2 (en) 2013-06-18
ES2676289T3 (es) 2018-07-18
IL209282A0 (en) 2011-01-31
MY160771A (en) 2017-03-15
GEP20135957B (en) 2013-11-11
PT2297114T (pt) 2018-07-26
UY31907A (es) 2010-01-29
CR20110001A (es) 2013-03-15
CO6300862A2 (es) 2011-07-21
US20110178057A1 (en) 2011-07-21
PL2297114T3 (pl) 2018-10-31
US8664380B2 (en) 2014-03-04
AU2009261153A1 (en) 2009-12-23
BRPI0914802A2 (pt) 2015-08-11
BRPI0914802B8 (pt) 2021-05-25
TWI472523B (zh) 2015-02-11
JP5918746B2 (ja) 2016-05-18
DK2297114T3 (en) 2018-07-09
CY1120995T1 (el) 2019-12-11
CN102123990B (zh) 2014-07-09
WO2009154300A2 (en) 2009-12-23
NZ589825A (en) 2012-11-30
JP2011524853A (ja) 2011-09-08
ZA201009073B (en) 2012-03-28
TWI378096B (en) 2012-12-01
EP2297114A2 (en) 2011-03-23
AR072166A1 (es) 2010-08-11
EA019755B1 (ru) 2014-06-30
RS57591B1 (sr) 2018-11-30
HUE039416T2 (hu) 2018-12-28
US20100137587A1 (en) 2010-06-03
MX2010013602A (es) 2011-03-15
CN103373985B (zh) 2015-10-28
CN103373985A (zh) 2013-10-30
BRPI0914802B1 (pt) 2020-10-27
SI2297114T1 (sl) 2018-10-30
US9045436B2 (en) 2015-06-02
JO3465B1 (ar) 2020-07-05
CA2728476A1 (en) 2009-12-23
US20120264733A1 (en) 2012-10-18
US20160046601A1 (en) 2016-02-18
TW201240987A (en) 2012-10-16
KR101578264B1 (ko) 2015-12-16
KR101207830B1 (ko) 2012-12-04
PE20110067A1 (es) 2011-02-18
NZ600238A (en) 2014-04-30
US20150191486A1 (en) 2015-07-09
MA32483B1 (fr) 2011-07-03
EA201170051A1 (ru) 2011-08-30
CN102123990A (zh) 2011-07-13
JP5592831B2 (ja) 2014-09-17
PE20140858A1 (es) 2014-08-04
JP2014094950A (ja) 2014-05-22
WO2009154300A3 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
DOP2013000123A (es) Compuesto heterocíclico y su uso.
PA8809001A1 (es) Compuestos organicos
NI201001031A (es) Formas cristalinas de dimetoxi docetaxel y metodo para preparar el mismo.
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
CL2011001333A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2009000426A1 (es) Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
UY32384A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
EA200801739A1 (ru) Индолопиридины в качестве модуляторов кинезина eg5
EA200801852A1 (ru) Индолопиридины в качестве модуляторов кинезина eg5
EA201100424A1 (ru) Новые ингибиторы
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
AR066268A1 (es) Compuesto de imidazol sustituido y su uso
PA8793201A1 (es) Pirimidinas bicíclicas fusinadas
UY31479A1 (es) 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su produccion y su uso como agentes antiinflamatorios
UY30488A1 (es) Bencilaminas,un proceso para su produccion y su uso como agentes anti-inflamatorios.
ATE499367T1 (de) 1,3-dihydroimidazol-2-thionderivate als inhibitoren von dopamin-beta-hydroxylase
CL2008002767A1 (es) Compuestos derivados de heterociclico triciclico; composicion farmaceutica; y su uso para el tratamiento de un trastorno mediado por serotonina tal como obesidad, esquizofrenia y disfuncion cognitiva.
ECSP088781A (es) Derivados de benzimidazol
NI201100035A (es) Agentes antifúngicos.
CL2012001758A1 (es) Uso de compuestos derivados de 8-hidroxiquinolin-7-carboxamida y sus sales, para el tratamiento y/o prevencion de infecciones fungicas.
UY32303A (es) Tiolactamas y sus usos
NO20091081L (no) Oganiske forbindelser